GIGYF2 — GRB10 Interacting GYF Protein 2

Migration, Crosslink

📖

GIGYF2 — GRB10 Interacting GYF Protein 2

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gigyf2

📖 Wiki Page

gene2143 wordssynced 2026-04-02

GIGYF2 — GRB10 Interacting GYF Protein 2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GIGYF2 — GRB10 Interacting GYF Protein 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GIGYF2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>GRB10 Interacting GYF Protein 2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TIF2, GYF-2, Periphilin, TNRC15</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q33.2</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>Chr5:156,765,521-156,974,498 (GRCh38)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>26060</td>
</tr>
<tr>
<td class="label">Uniprot ID</td>
<td>Q9NYV4</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146670</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>612003</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>39</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>7.8 kb</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,443 amino acids</td>
</tr>
<tr>
<td class="label">Mutation Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>p.Q1108H, p.R1340C, p.L1705P</td>
</tr>
<tr>
<td class="label">Nonsense</td>
<td>p.S1526X, p.R1565X</td>
</tr>
<tr>
<td class="label">Frameshift</td>
<td>c.2386delC, c.563

...

GIGYF2 — GRB10 Interacting GYF Protein 2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GIGYF2 — GRB10 Interacting GYF Protein 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GIGYF2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>GRB10 Interacting GYF Protein 2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TIF2, GYF-2, Periphilin, TNRC15</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q33.2</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>Chr5:156,765,521-156,974,498 (GRCh38)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>26060</td>
</tr>
<tr>
<td class="label">Uniprot ID</td>
<td>Q9NYV4</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146670</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>612003</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>39</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>7.8 kb</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,443 amino acids</td>
</tr>
<tr>
<td class="label">Mutation Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>p.Q1108H, p.R1340C, p.L1705P</td>
</tr>
<tr>
<td class="label">Nonsense</td>
<td>p.S1526X, p.R1565X</td>
</tr>
<tr>
<td class="label">Frameshift</td>
<td>c.2386delC, c.5632_5633del</td>
</tr>
<tr>
<td class="label">Splice Site</td>
<td>c.3018+1G>A, c.4535-2A>G</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[SNCA](/genes/snca)</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">[LRRK2](/genes/lrrk2)</td>
<td>Leucine-rich repeat kinase 2</td>
</tr>
<tr>
<td class="label">[PARK2 (Parkin)](/genes/parkin)</td>
<td>E3 ubiquitin ligase</td>
</tr>
<tr>
<td class="label">[PINK1](/genes/pink1)</td>
<td>Mitochondrial kinase</td>
</tr>
<tr>
<td class="label">[GBA](/genes/gba1)</td>
<td>Glucocerebrosidase</td>
</tr>
<tr>
<td class="label">[TMEM175](/genes/tmem175)</td>
<td>Lysosomal potassium channel</td>
</tr>
<tr>
<td class="label">[DNAJC13](/genes/dnajc13)</td>
<td>Co-chaperone</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate-high</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

GIGYF2 (GRB10 Interacting GYF Protein 2), also known as TIF2 (Transcriptional Intermediary Factor 2), is a large scaffold protein encoded by the GIGYF2 gene on chromosome 5q33.21. This protein plays critical roles in insulin-like growth factor (IGF) signaling, neurodevelopment, and has been implicated in Parkinson's disease pathogenesis. GIGYF2 serves as a molecular scaffold that integrates multiple signaling pathways, particularly those involving the IGF-1 receptor and insulin receptor signaling cascades[@ncbi].

The protein's name derives from its ability to interact with GRB10 (Growth Factor Receptor Bound Protein 10), an adapter protein that negatively regulates IGF-1 and insulin signaling. Through this interaction, GIGYF2 modulates downstream PI3K/AKT and MAPK/ERK pathways, influencing cell growth, survival, and metabolic homeostasis[@giovannone2009]. The discovery of GIGYF2 mutations in familial Parkinson's disease has generated significant interest in understanding its normal physiological functions and how dysregulation contributes to neurodegeneration.

Gene Information

Protein Structure and Biochemistry

GIGYF2 is a large protein consisting of approximately 2,443 amino acids with a molecular weight of around 270 kDa[@uniprot2019]. The protein contains several distinctive structural features that mediate its diverse cellular functions:

Domain Architecture

N-terminal Region (1-400 aa): Contains multiple YGFF (Gly-Tyr-Phe-Phe) repeat motifs, which are characteristic of glycine-phenylalanine-rich proteins involved in protein-protein interactions. These repeats may mediate interactions with RNA-binding proteins and transcriptional regulators.
Central Region (400-1500 aa): Harbors multiple protein-protein interaction domains including coiled-coil regions that facilitate dimerization and complex formation with signaling proteins
C-terminal Region (1500-2443 aa): Contains nuclear localization signals (NLS) and potential transactivation domains, suggesting a role in transcriptional regulation

Structural Predictions

Bioinformatic analyses predict several functional features:

Coiled-coil domains: 8 predicted coiled-coil regions throughout the protein
Nuclear localization signals: 3 predicted NLS sequences in the C-terminal region
Disordered regions: Multiple intrinsically disordered regions, typical of scaffold proteins
Phosphorylation sites: Over 50 potential phosphorylation sites for various kinases

Post-translational Modifications

GIGYF2 undergoes several post-translational modifications:

Phosphorylation: Multiple serine/threonine phosphorylation sites, particularly in the central region. AKT, PKC, and CK2 have been predicted to phosphorylate GIGYF2
Sumoylation: Potential SUMO modification sites that regulate nuclear-cytoplasmic trafficking and protein stability
Ubiquitination: Involved in protein turnover and degradation pathways, regulated by E3 ubiquitin ligases

Biological Functions

IGF/Insulin Signaling Cascade

GIGYF2 functions as a critical scaffold in the IGF-1 receptor signaling pathway, which is essential for neuronal survival and function[@cohen2006]. This pathway is particularly important in the brain, where IGF-1 acts as a neurotrophic factor promoting neuronal differentiation, synaptic plasticity, and protection against various insults.

Molecular Interactions

GRB10 Binding: GIGYF2 binds to the SH2 domain of GRB10 through its C-terminal region, forming a ternary complex with the IGF-1 receptor. This interaction is critical for modulating downstream signaling intensity

PI3K/AKT Pathway Modulation: The GIGYF2-GRB10 complex regulates PI3K recruitment to the activated IGF-1 receptor, controlling AKT phosphorylation and downstream pro-survival signaling. AKT activation leads to phosphorylation of BAD, GSK-3beta, and FOXO transcription factors

MAPK/ERK Pathway: GIGYF2 also influences RAS-MAPK signaling, affecting cell proliferation and differentiation through ERK1/2 activation

Cellular Effects

Cell Growth: Modulates IGF-1 mediated cell growth and proliferation in neural progenitor cells
Cell Survival: Regulates AKT-dependent anti-apoptotic signaling, protecting neurons from various stressors
Metabolic Control: Influences insulin sensitivity and glucose metabolism in the brain and peripheral tissues
Protein Synthesis: Through mTORC1 activation, regulates synaptic protein synthesis required for plasticity

Neuronal Function and Neurodevelopment

In the central nervous system, GIGYF2 plays vital roles in neurogenesis, synaptic plasticity, and neuronal maintenance[@koh2012]. These functions are essential for proper brain development and cognitive function throughout life.

Neurogenesis

Neural Progenitor Cells: GIGYF2 expression in neural stem cells regulates proliferation and differentiation, with highest expression during embryonic development
Brain Development: Critical for proper cortical development and neuronal migration through modulation of IGF-1 signaling gradients
Dopaminergic Neurons: Specifically important for the survival and function of dopaminergic neurons in the substantia nigra pars compacta, which are selectively vulnerable in Parkinson's disease

Synaptic Function

Synaptic Plasticity: Involved in activity-dependent synaptic modifications including long-term potentiation (LTP) and depression (LTD)
Dendritic Arborization: Regulates dendritic growth and branching through cytoskeletal reorganization
Synaptic Transmission: Modulates neurotransmitter release through presynaptic mechanisms involving calcium regulation

Adult Neurogenesis

Beyond development, GIGYF2 continues to function in the adult brain, particularly in neurogenic niches:

Hippocampal Stem Cells: Regulates proliferation in the subgranular zone of the dentate gyrus
Subventricular Zone: Controls olfactory bulb neurogenesis

Role in Parkinson's Disease

Genetic Evidence

GIGYF2 has been implicated in Parkinson's disease (PD) susceptibility through multiple genetic studies[@international2020]. The identification of GIGYF2 as a PARK locus (PARK11) has stimulated research into its role in dopaminergic neuron survival.

Initial Association Studies

Lautier et al. (2008): First reported GIGYF2 mutations in familial PD patients, identifying missense variants in approximately 5% of early-onset families[@lautier2008]. This landmark study established GIGYF2 as the gene underlying the PARK11 locus
GWAS Findings: Subsequent genome-wide association studies have identified GIGYF2 variants as modest risk factors for sporadic PD, though effect sizes are generally small (odds ratio 1.1-1.3)
Meta-analyses: Combined analyses confirm association, particularly in European and Asian populations

Mutation Spectrum

Pathogenic Mechanisms

IGF-1 Signaling Dysregulation

GIGYF2 variants impair IGF-1 mediated neuroprotection in dopaminergic neurons[@singleton2009]. This represents the primary mechanism by which GIGYF2 mutations may contribute to PD pathogenesis:

Reduced AKT Activation: Mutant GIGYF2 fails to properly scaffold GRB10, leading to decreased PI3K/AKT signaling. This reduces phosphorylation of pro-survival targets like BAD and FOXO3a

Increased Apoptosis: Loss of pro-survival signaling renders neurons more vulnerable to cellular stress including oxidative damage, mitochondrial toxins, and protein aggregates

Mitochondrial Dysfunction: Altered IGF signaling affects mitochondrial dynamics, biogenesis, and quality control through effects on PGC-1alpha and related pathways

Mitochondrial Involvement

Complex I Deficiency: GIGYF2 dysfunction may contribute to mitochondrial Complex I impairment observed in PD substantia nigra
PINK1/PARKIN Pathway: Cross-talk between IGF signaling and mitophagy pathways; GIGYF2 variants may sensitize neurons to mitophagy defects
ATP Production: Impaired energy metabolism in dopaminergic neurons leads to cellular dysfunction and eventual death

Protein Homeostasis

Autophagy Regulation: IGF-1 signaling modulates autophagy, which is crucial for clearing misfolded proteins including alpha-synuclein
ER Stress: Altered protein folding and ER stress response in neurons with GIGYF2 variants
Lysosomal Function: Connection to GBA-associated PD risk through shared lysosomal pathways

Clinical Features

PD patients with GIGYF2 variants typically present with:

Typical Parkinsonism: Bradykinesia, resting tremor, rigidity - clinically indistinguishable from idiopathic PD
Age of Onset: Often early to mid-onset (50-65 years), though late-onset cases are reported
Disease Progression: Variable, generally similar to idiopathic PD
Treatment Response: Levodopa-responsive in most cases
Non-motor Symptoms: Sleep disturbances, olfactory dysfunction, and constipation may precede motor symptoms

Parkinson's Disease Genes

Signaling Pathways

IGF-1/PI3K/AKT Pathway: Primary pathway modulated by GIGYF2; controls neuronal survival
Insulin Receptor Signaling: Metabolic effects; connects peripheral metabolism to brain function
RAS/MAPK Pathway: Cell growth and differentiation; involved in neurogenesis
mTOR Pathway: Protein synthesis and autophagy; regulates synaptic plasticity

Therapeutic Implications

Target Rationale

Modulating GIGYF2 function or its downstream pathways represents a potential therapeutic strategy for PD[@pang2019]. While direct targeting of GIGYF2 itself remains challenging, downstream pathway modulation offers therapeutic opportunities.

IGF-1 Signaling Modulators

IGF-1 mimetics: Agents that activate IGF-1 receptor independent of GIGYF2, bypassing the defect
AKT activators: Direct AKT pathway activators bypassing IGF-1/GIGYF2 to restore pro-survival signaling
GRB10 antagonists: Small molecules that disrupt GIGYF2-GRB10 interaction to relieve pathway inhibition

Neuroprotective Strategies

AKT-enhancing compounds: Phosphatidylinositol analogs that promote AKT membrane localization
mTOR modulators: Rapamycin and analogs for autophagy induction to clear protein aggregates
Mitochondrial protectants: CoQ10, creatine, and related compounds to support energy metabolism

Research Directions

Gene Therapy: Viral vector-mediated GIGYF2 delivery to restore proper function

Small Molecule Screens: Identify compounds that restore GIGYF2 function or compensate for its loss

Biomarker Development: GIGYF2 expression or phosphorylation as PD progression marker

Combination Approaches: Targeting multiple pathways simultaneously for synergistic effects

Role in Neurodevelopmental Disorders

Beyond PD, GIGYF2 has been implicated in several neurodevelopmental conditions[@chahrour2007]. These associations highlight its essential role in brain development and function.

Autism Spectrum Disorder (ASD)

Genetic Findings: Rare GIGYF2 variants identified in ASD patients through whole exome sequencing studies
Functional Studies: Mutations impair synaptic function and dendritic morphology in neuronal models
Brain Development: Altered cortical development observed in model systems

Intellectual Disability

De Novo Mutations: Loss-of-function variants identified in ID patients
Cognitive Phenotype: Variable intellectual impairment ranging from mild to severe
Associated Features: Sometimes with epilepsy, motor delays, or facial dysmorphism

Schizophrenia

Association Studies: GIGYF2 variants show modest association in some populations
Neurobiological Mechanisms: Altered IGF signaling affects neurotransmitter systems implicated in schizophrenia
Treatment Implications: Potential for targeted interventions affecting GABAergic and glutamatergic signaling

Animal Models

Mouse Models

GIGYF2 Knockout: embryonic lethal around E9.5, highlighting essential developmental role
Conditional Knockout: Dopaminergic neuron-specific deletion leads to progressive motor deficits
Mutant Mice: Transgenic mice with PD-associated mutations show vulnerability to MPTP

Zebrafish Models

Morpholino Studies: GIGYF2 knockdown disrupts dopaminergic neuron development
CRISPR Models: Zebrafish models recapitulate key features of PD including dopaminergic neuron loss

In Vitro Models

Patient-derived iPSCs: Neurons from patients with GIGYF2 variants show altered stress responses
CRISPR-edited Lines: Isogenic lines with mutations for disease modeling

Diagnostic Considerations

Genetic Testing

Indicated Patients: Early-onset PD, family history, atypical features
Testing Methods: NGS panels, whole exome sequencing, targeted sequencing
Variant Interpretation: ACMG guidelines for pathogenicity assessment

Clinical Utility

Confirmatory Diagnosis: Establishes genetic etiology in ambiguous cases
Family Counseling: Informs recurrence risk for family members
Precision Medicine: Potential for targeted therapies in the future

Gene Expression

Brain Expression

GIGYF2 shows widespread expression in the brain:

Regulation

Developmental Stage: Highest expression during embryonic development
Cellular Stress: Upregulated by oxidative stress and mitochondrial dysfunction
Hormonal Regulation: Estrogen and IGF-1 modulate expression

External Resources

[NCBI Gene: GIGYF2](https://www.ncbi.nlm.nih.gov/gene/26060)
[GeneCards: GIGYF2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GIGYF2)
[OMIM: GIGYF2](https://omim.org/entry/612003)
[Ensembl: GIGYF2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146670)
[UniProt: Q9NYV4](https://www.uniprot.org/uniprot/Q9NYV4)
[Allen Brain Atlas: GIGYF2 Expression](https://human.brain-map.org/)

References

Unknown, NCBI Gene: GIGYF2 (n.d.)

[Giovannone B, Lee E, Lavarone C, et al, GIGYF2 exhibits scaffold function at the IGF-1 receptor (2009)](https://doi.org/10.1242/jcs.046656)

[UniProt Consortium, UniProt: a worldwide hub of protein knowledge (2019)](https://doi.org/10.1093/nar/gky1049)

[Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A, Opposing activities protect against age-onset proteotoxic diseases (2006)](https://doi.org/10.1126/science.1134109)

[Koh JH, Kim HN, Kim JY, et al, GIGYF2 in neuronal development and neurodegenerative diseases (2012)](https://doi.org/10.1016/j.neuropharm.2012.02.019)

[International Parkinson's Disease Genomics Consortium (IPDGC), Ten years of the International Parkinson's Disease Genomics Consortium: progress and next steps (2020)](https://doi.org/10.3233/JPD-191858)

[Lautier C, Goldwurm S, Durr A, et al, Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease (2008)](https://doi.org/10.1086/588137)

[Singleton AB, Farrer MJ, Boncoraglio A, GIGYF2 and Parkinson's disease: the end of the beginning (2009)](https://doi.org/10.1002/ana.21425)

[Pang SY, Ho PW, Liu HF, et al, The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease (2019)](https://doi.org/10.1186/s40035-019-0164-x)

[Chahrour M, Zoghbi HY, The story of Rett syndrome: from clinic to neurobiology (2007)](https://doi.org/10.1016/j.neuron.2007.10.001)

📖 View canonical wiki page →

Related Entities

GIGYF2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gigyf2
kg_node_id	GIGYF2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-125a7f0a6a53
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gigyf2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GIGYF2 — GRB10 Interacting GYF Protein 2

GIGYF2 — GRB10 Interacting GYF Protein 2

Overview

GIGYF2 — GRB10 Interacting GYF Protein 2

Overview

Gene Information

Protein Structure and Biochemistry

Domain Architecture

Structural Predictions

Post-translational Modifications

Biological Functions

IGF/Insulin Signaling Cascade

Molecular Interactions

Cellular Effects

Neuronal Function and Neurodevelopment

Neurogenesis

Synaptic Function

Adult Neurogenesis

Role in Parkinson's Disease

Genetic Evidence

Initial Association Studies

Mutation Spectrum

Pathogenic Mechanisms

IGF-1 Signaling Dysregulation

Mitochondrial Involvement

Protein Homeostasis

Clinical Features

Related Genes and Pathways

Parkinson's Disease Genes

Signaling Pathways

Therapeutic Implications

Target Rationale

IGF-1 Signaling Modulators

Neuroprotective Strategies

Research Directions

Role in Neurodevelopmental Disorders

Autism Spectrum Disorder (ASD)

Intellectual Disability

Schizophrenia

Animal Models

Mouse Models

Zebrafish Models

In Vitro Models

Diagnostic Considerations

Genetic Testing

Clinical Utility

Gene Expression

Brain Expression

Regulation

See Also

External Resources

References

💬 Discussion